Otonomy Reports Second Quarter 2015 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 12, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended June 30, 2015 and provided an update on its corporate activities and product pipeline.
Read More

ZS Pharma Reports Second Quarter 2015 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE)ZS Pharma, Inc. (Nasdaq:ZSPH), today reported its financial results for the second quarter ended June 30, 2015, and provided an overview of recent accomplishments.

Read More

Tryton Medical Announces Completion of Enrollment in the EXTENDED ACCESS Registry for its Tryton Side Branch Stent

Tryton remains on schedule to file pre-market approval application for its Side Branch Stent in 2015

DURHAM, N.C.–(BUSINESS WIRE [1])–August 3, 2015–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the completion of enrollment in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. The Tryton registry is designed to confirm the results from Tryton’s Pivotal IDE Trial, and has successfully enrolled 133 patients from Europe and the United States.

Read More

ZS Pharma Announces FDA Acceptance of ZS-9 New Drug Application

REDWOOD CITY, Calif., July 29, 2015 (GLOBE NEWSWIRE) ZS Pharma, Inc. (Nasdaq:ZSPH), today announced that its New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, has been accepted for filing by the United States Food and Drug Administration (FDA).

Read More